NCT01795313View on ClinicalTrials.gov

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides with Imiquimod

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Ependymoma
Interventions
BIOLOGICAL

HLA-A2 restricted synthetic tumor antigen

DRUG

Imiquimod

OTHER

enzyme-linked immunosorbent assay

OTHER

flow cytometry

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Trial Locations (1)

15224

RECRUITING

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

Sponsors

Lead Sponsor

James Felker
All Listed Sponsors
collaborator

Solving Kids' Cancer

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

James Felker

OTHER

NCT01795313 - Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides with Imiquimod | Biotech Hunter | Biotech Hunter